Cargando…

Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients

BACKGROUND: We investigated whether early dynamic changes of circulating free (cfDNA) levels as well as the neutrophil to lymphocyte ratio (NLR) could predict nivolumab effectiveness in pretreated patients with advanced non-small cell lung cancer (NSCLC). METHODS: A total of 45 patients receiving ni...

Descripción completa

Detalles Bibliográficos
Autores principales:	Passiglia, Francesco, Galvano, Antonio, Castiglia, Marta, Incorvaia, Lorena, Calò, Valentina, Listì, Angela, Mazzarisi, Salvatore, Perez, Alessandro, Gallina, Giuseppe, Rizzo, Sergio, Soto Parra, Hector, Bazan, Viviana, Russo, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469277/ https://www.ncbi.nlm.nih.gov/pubmed/31019571 http://dx.doi.org/10.1177/1758835919839928

Ejemplares similares

The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis
por: Passiglia, Francesco, et al.
Publicado: (2018)

Publisher Correction: The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis
por: Passiglia, Francesco, et al.
Publicado: (2018)

PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis
por: Passiglia, Francesco, et al.
Publicado: (2016)

“Back to a false normality”: new intriguing mechanisms of resistance to PARP inhibitors
por: Incorvaia, Lorena, et al.
Publicado: (2016)

Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway
por: Massihnia, Daniela, et al.
Publicado: (2016)

Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus
por: Cabibi, Daniela, et al.
Publicado: (2016)

Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)
por: Incorvaia, Lorena, et al.
Publicado: (2019)

Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?—a trial-level meta-analysis in PD-L1 selected subgroups
por: Passiglia, Francesco, et al.
Publicado: (2021)

Are Long Noncoding RNAs New Potential Biomarkers in Gastrointestinal Stromal Tumors (GISTs)? The Role of H19 and MALAT1
por: Badalamenti, Giuseppe, et al.
Publicado: (2019)

Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis
por: Galvano, Antonio, et al.
Publicado: (2019)

How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis
por: Galvano, Antonio, et al.
Publicado: (2019)

Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?
por: Fanale, Daniele, et al.
Publicado: (2016)

Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study
por: Gristina, Valerio, et al.
Publicado: (2022)

The diagnostic accuracy of PIK3CA mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysis
por: Galvano, Antonio, et al.
Publicado: (2022)

New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?
por: Bronte, Giuseppe, et al.
Publicado: (2015)

Hereditary Breast and Ovarian Cancer in Families from Southern Italy (Sicily)—Prevalence and Geographic Distribution of Pathogenic Variants in BRCA1/2 Genes
por: Incorvaia, Lorena, et al.
Publicado: (2020)

Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay
por: Incorvaia, Lorena, et al.
Publicado: (2023)

Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma
por: Incorvaia, Lorena, et al.
Publicado: (2016)

Potential Role of ANGPTL4 in the Cross Talk between Metabolism and Cancer through PPAR Signaling Pathway
por: La Paglia, Laura, et al.
Publicado: (2017)

Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions
por: Incorvaia, Lorena, et al.
Publicado: (2020)

Analysis of miRNA expression profile induced by short term starvation in breast cancer cells treated with doxorubicin
por: Rizzo, Sergio, et al.
Publicado: (2017)

Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses
por: Gristina, Valerio, et al.
Publicado: (2021)

Stabilizing versus Destabilizing the Microtubules: A Double-Edge Sword for an Effective Cancer Treatment Option?
por: Fanale, Daniele, et al.
Publicado: (2015)

Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials
por: Galvano, Antonio, et al.
Publicado: (2019)

Focus on Nivolumab in NSCLC
por: Cortinovis, Diego L., et al.
Publicado: (2016)

Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2
por: Fanale, Daniele, et al.
Publicado: (2020)

Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score
por: Galvano, Antonio, et al.
Publicado: (2020)

Moving the Target on the Optimal Adjuvant Strategy for Resected Pancreatic Cancers: A Systematic Review with Meta-Analysis
por: Galvano, Antonio, et al.
Publicado: (2020)

Reply to: Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials (Galvano et al., J Bone Oncol 2019; 18:100252)
por: Galvano, Antonio, et al.
Publicado: (2020)

The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer
por: Gristina, Valerio, et al.
Publicado: (2020)

Safety and effectiveness of gemcitabine for the treatment of classic Kaposi’s sarcoma without visceral involvement
por: Badalamenti, Giuseppe, et al.
Publicado: (2022)

Immunological Aspects of Von Hippel-Lindau Disease: A Focus on Neuro-Oncology and Myasthenia Gravis
por: Norata, Davide, et al.
Publicado: (2023)

The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials
por: Galvano, A., et al.
Publicado: (2021)

Clinical parameters to guide decision-making in elderly metastatic colorectal cancer patients treated with intensive cytotoxic and anti-angiogenic therapy
por: Bruera, Gemma, et al.
Publicado: (2016)

MET Amplification and Efficacy of Nivolumab in Patients With NSCLC
por: Yoshimura, Katsuhiro, et al.
Publicado: (2021)

Stereotaktische Radiotherapie plus Nivolumab bei NSCLC
por: Krug, David, et al.
Publicado: (2023)

Optimizing the clinical management of EGFR-mutant advanced non-small cell lung cancer: a literature review
por: Passiglia, Francesco, et al.
Publicado: (2022)

Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors
por: Dimino, Alessandra, et al.
Publicado: (2022)

One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients
por: Badalamenti, Giuseppe, et al.
Publicado: (2019)

BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype–phenotype correlation in a cohort of 531 patients
por: Incorvaia, Lorena, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ua4ronfnibbncfldk20vu4t480